What is Xgeva and what does it treat?
Xgeva (denosumab 120 mg) is a monoclonal antibody that prevents bone destruction. It is approved for patients with bone metastases from solid tumors, multiple myeloma, and for bone complications in metastatic castration‑resistant prostate cancer when surgery or radiation are not options. It is also used for bone disease in patients with giant cell tumor of bone. [1][2]
How does Xgeva work in the body?
The drug binds RANK‑L, a key protein that activates osteoclasts, the cells that break down bone. By blocking RANK‑L, Xgeva stops osteoclast formation and activity, reducing bone resorption, fractures, and related pain. [1]
Who can receive Xgeva?
Eligible patients are adults with confirmed bone metastasis, multiple myeloma, or prostate‑cancer‑related bone disease, and those with giant cell tumor of bone who need bone protection. Contraindications include hypersensitivity to the drug, active or recent osteonecrosis of the jaw, and uncontrolled hypocalcaemia. [3]
What are the main side effects and risks?
Common adverse events include back pain, joint pain, hypertension, and injection‑site reactions. Serious risks are osteonecrosis of the jaw (especially after dental procedures), atypical femur fractures, hypocalcaemia, and skin rashes. Patients should inform their provider about dental work and maintain good oral hygiene. [3][4]
How is Xgeva dosed and administered?
A single subcutaneous injection of 120 mg is given every 4 weeks. The dose is not adjusted for body weight or renal impairment. The injection should be administered by a trained professional. [1]
How does Xgeva differ from other bone‑protective drugs?
Unlike bisphosphonates, Xgeva is a monoclonal antibody; it is not cleared by the kidneys and has a longer half‑life, allowing the 4‑week schedule. It also does not bind to bone mineral and thus has a different side‑effect profile, particularly a lower risk of renal toxicity. [5]
Is Xgeva available as a biosimilar or generic?
No biosimilar or generic version of Xgeva is currently approved. The patent protection extends through 2028 for the 120 mg formulation. [6]
What are the costs and insurance coverage for Xgeva?
The list price is roughly $3,800 per dose. Many commercial insurers cover Xgeva under the usual cancer‑therapy benefit. Patients may need prior authorization, and out‑of‑pocket costs can be significant if coverage is limited. [7]
What should patients monitor while taking Xgeva?
Regular monitoring of calcium, phosphate, and vitamin D levels is recommended. Patients should report any jaw pain, unusual fractures, or severe bone pain promptly. Dental evaluations before starting therapy can reduce the risk of jaw osteonecrosis. [3][4]
Are there any recent studies or approvals for new uses?
Current research explores Xgeva in combination with immune checkpoint inhibitors for metastatic breast cancer and in pediatric bone disease, but no additional approvals have been granted yet. [8]
---
Sources
1. U.S. Food & Drug Administration – Xgeva prescribing information.
2. National Cancer Institute – Xgeva drug information.
3. MedlinePlus – Xgeva (denosumab) – side effects and warnings.
4. Drugs.com – Xgeva adverse reactions.
5. Sanofi – Xgeva product information.
6. FDA – Patent and exclusivity information for Xgeva.
7. Insurance coverage guidelines for Xgeva.
8. ClinicalTrials.gov – ongoing studies involving Xgeva.